Novel Suppository Design for HIV Chemoprophylaxis - Pharmaceutical Technology

Latest Issue

Latest Issue
PharmTech Europe

Novel Suppository Design for HIV Chemoprophylaxis
Technical Note: The authors investigated the variables important for calcium-alginate formation as well as dissolution.

Pharmaceutical Technology
Volume 34, Issue 7, pp. 68-69, 72

Results and conclusion

Figure 1: Dissolution in citrate of 0.5 and 2.0% calcium-alginate gels containing aurintricarboxylic acid (1 mg/mL). (FIGURES ARE COURTESY OF T.J. SMITH)
Within the range of calcium and alginate tested, alginate was confirmed as the most important formulation variable in this system and was associated with the greatest change in dissolution time (see Figures 1 and 2). Variation in calcium yielded little change in the dissolution time (see Figure 2).

Figure 2: Effect of calcium chloride on the citrate-mediated dissolution of 0.5 and 2.0% alginate gels. The citrate concentration was 132 mM.
Although a single concentration of ATA was used, variations in the concentration of this polyanion must be considered if ATA and its derivatives are to be advanced for preclinical or clinical evaluation. Nevertheless, these results reflect the importance of alginate-concentration changes, regardless of the anti-HIV agent under consideration. The results also verified the importance of citrate concentration because dissolution time appeared to be inversely proportional to citrate concentration (see Figure 1). Citrate in seminal fluid at a concentration of ~132 mM) is reduced by as much as 50% in certain disease processes (7). While this reduction in citrate would be expected to decrease the release rate of drug from the formulation, total dissolution occurred at both citrate concentrations. Microgranular cellulose yielded suppositories of a prototype that may yield sustained-release characteristics in the presence of citrate. The properties of the suppositories and the dissolution time are summarized in Table I.

Table I: Characteristics of manually fabricated prototype suppositories.
In addition to its utility to viscosity enhancement for manual fabrication of the prototype suppositories, cellulose is relatively inexpensive and safe to use for intravaginal and intrarectal applications (4, 5). This formulation's capability to alter release rates for anti-HIV drugs, as well as the simplicity of design, deserves further consideration and investigation.

Timothy J. Smith* is a professor and chair of the Department of Physiology and Pharmacology, and Lara Haddad, Soraia Faizyar, Evelyn Valdez, Elizabeth Gramer, Layla S. Derreja, and Stefany M. Bowers are doctoral students, all at Thomas J. Long School of Pharmacy, University of the Pacific, Stockton, CA 95211, tel. 209.946.3168, fax 209.946.2857,

*To whom all correspondence should be addressed.

Submitted: Aug. 25, 2009. Accepted: Oct. 7, 2009.


1. K. Fong and T.J. Smith, Pharm. Dev. Technol. 14 (4), 341–342 (2009).

2. M. Cushman et al., J. Med. Chem. 34 (1), 329–337 (1991).

3. J. LaBonte, J. Lebbos, and P. Kirkpatrick, Nat. Rev. Drug Discov. 2 (5), 345–346 (2003).

4. A.R. Neurath, N. Engl. J. Med. 359 (19), 2066–2067 (2008).

5. V.M.K. Ndesendo et al., AAPS PharmSciTech. 9 (2), 505–520 (2008).

6. T.J. Smith, Curr. Top. Biotechnol. 1, 129–132 (2004).

7. E.E. Kline et al., J. Urol. 176 (5), 2274–2279 (2006).


blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
| Weekly

What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Jim Miller Outsourcing Outlook Jim MillerOutside Looking In
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAdvances in Large-Scale Heterocyclic Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler New Era for Generic Drugs
Sean Milmo European Regulatory WatchSean MilmoTackling Drug Shortages
New Congress to Tackle Health Reform, Biomedical Innovation, Tax Policy
Combination Products Challenge Biopharma Manufacturers
Seven Steps to Solving Tabletting and Tooling ProblemsStep 1: Clean
Legislators Urge Added Incentives for Ebola Drug Development
FDA Reorganization to Promote Drug Quality
Source: Pharmaceutical Technology,
Click here